Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices

The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but...

Full description

Bibliographic Details
Main Authors:	L. V. Bolotina, A. D. Kaprin
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-11-01
Series:	Медицинский совет
Subjects:	metastatic colorectal cancer (mcrc) targeted therapy aflibercept
Online Access:	https://www.med-sovet.pro/jour/article/view/2742

Similar Items

The optimization of second-line therapy for metastatic colorectal cancer: new targeted therapy options
by: E V Artamonova, et al.
Published: (2016-03-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
by: Kei Muro, et al.
Published: (2020-03-01)

Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency
by: R. T. Ayupov, et al.
Published: (2021-12-01)

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience
by: Govind Babu, et al.
Published: (2016-01-01)

Aflibercept as a treatment for malignant tumors
by: V. A. Ivanov, et al.
Published: (2022-03-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Optimal Sequence and Second-Line Systemic Treatment of Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis
by: Chih-Chien Wu, et al.
Published: (2021-11-01)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
by: Alessandro Parisi, et al.
Published: (2020-05-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Clinicopathological Profiles Associated with Discordant <i>RAS</i> Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
by: Elena Brozos-Vázquez, et al.
Published: (2023-07-01)

Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review
by: Jan Gerard Maring, et al.
Published: (2023-02-01)

Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
by: A. D. Darenskaya, et al.
Published: (2018-11-01)

Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line
by: Salah Mabrook Khallaf, et al.
Published: (2024-01-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis
by: Majed Ramadan, et al.
Published: (2022-01-01)

The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
by: I V Poddubnaya, et al.
Published: (2014-03-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY
by: M. Yu. Fedyanin, et al.
Published: (2015-05-01)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
by: Jorge Aparicio, et al.
Published: (2020-11-01)

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
by: Wen-Hui Xue, et al.
Published: (2023-05-01)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
by: Prashanth Rawla, et al.
Published: (2019-07-01)

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
by: Gemma Bruera, et al.
Published: (2020-08-01)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
by: Ting-Yu Chiang, et al.
Published: (2023-03-01)

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
by: Ian Chau, et al.
Published: (2020-03-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
by: John H. Strickler, et al.
Published: (2019-11-01)

Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
by: Pu Ge, et al.
Published: (2022-08-01)

Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer
by: A. A. Tryakin, et al.
Published: (2018-11-01)

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
by: Karen Gambaro, et al.
Published: (2023-12-01)

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
by: Rebersek Martina, et al.
Published: (2019-03-01)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
by: Daniele Lavacchi, et al.
Published: (2021-07-01)

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Albert Tuca, et al.
Published: (2020-12-01)

Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer
by: K. A. Vorontsova, et al.
Published: (2015-12-01)

Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer
by: Rhynelle S. Dmello, et al.
Published: (2021-02-01)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
by: María San-Román-Gil, et al.
Published: (2023-01-01)

Second line anti-cancer therapy for metastatic colorectal cancer: treatment strategy
by: K. A. Vorontsova, et al.
Published: (2015-12-01)

Antibody targeting of claudin-1 as a potential colorectal cancer therapy
by: S. Cherradi, et al.
Published: (2017-06-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)